Nu Skin Enterprises (NUS) delivered a quarter that management called on-plan and the Street will likely see as another step down. Adjusted EPS of $0.10 missed the $0.21 consensus by 52.4% and fell 70.6% from a year ago. Revenue of $311.01 million came in 5.4% below the $328.7 million consensus and declined 14.6% year over year. On a GAAP basis, the company swung from a $0.34 profit to a $(0.02) loss. Management emphasized that revenue landed within its own guidance range. That framing does little to offset the central problem: the company cut full-year guidance for the third consecutive time and quietly dropped its long-promised return to growth.

The quality of the quarter is weaker than the consolidated figures suggest. The core Nu Skin business fell 19.2%, or 18.0% in constant currency. That is a sharp deterioration from the 15.3% decline over the first nine months, so the contraction accelerated rather than stabilized. The damage was broad:

• South Korea fell 30.7%.
• Europe & Africa dropped 26.6%.
• Southeast Asia/Pacific declined 23.5%.
• The Americas fell 17.0%.

What cushioned the total was Rhyz manufacturing, up 19.3%. That growth carries structural costs. Because manufacturing revenue earns far lower margins, consolidated gross margin compressed to 65.0% from 70.5%. More tellingly, core gross margin also slipped to 76.6% from 77.7%, after posting year-over-year gains in the first two quarters. Adjusted operating margin fell to 3.7% from 5.9% a year ago and 6.1% in Q2. G&A rose to 30.2% of revenue even though G&A dollars fell $10.9 million, a sign that cost cuts are trailing the revenue decline. A 42.7% adjusted tax rate further squeezed what little pre-tax profit remained.

The forward-looking numbers carry the most weight. Full-year revenue guidance is now $1.26-$1.29 billion, down from $1.28-$1.35 billion in August and $1.35-$1.50 billion at the start of the year. Adjusted EPS guidance falls to $0.55-$0.65, down from $0.70-$0.90 and an original $0.80-$1.20. The adjusted tax-rate assumption rose to about 39% from 35%. Fourth-quarter guidance of $310-$340 million implies the sequential growth the CEO highlighted, but it still represents an 8% to 16% year-over-year decline. The pipeline does not suggest a near-term turn:

• Customers fell 18%, with the Americas down 27%.
• Paid affiliates declined 10%.
• Sales leaders dropped 13%.

Management acknowledged on the call that these metrics remain under pressure.

The Prysm iO platform is the key exhibit in both the bull and bear arguments. On the positive side, the 2.0 app with AI integration, launched in late August, more than doubled scan-to-purchase conversion to 10%. Cumulative scans reached 4.5 million, up from 2.5 million at the Q2 call, and flagship LifePak sales are up nearly 3% year to date. The problem is hardware adoption. Device placements reached only about 41,000, versus 39,000 a quarter earlier. Management did not reiterate the 50,000-60,000 year-end target, which had itself been cut from 100,000. The product appears to work for users who have it, but distribution is stalling. Other catalysts are distant: women's health anti-aging products previewed at the Japan convention will not roll out until mid-2027, and the India launch had already slipped to the first half of 2027.

The balance sheet adds to the pressure. Cash fell to $164.9 million, down from $189.6 million in Q2 and roughly $239 million at year-end. Debt did decline to about $204 million. The company repurchased no stock and expects roughly $5 million in additional transition charges in the fourth quarter. The CFO role remains interim. Bears have legitimate ammunition here: a shrinking core, eroding margins and a steadily lower earnings base, all while the company is restructuring.

The market setup was already skeptical. Investor sentiment improved only marginally ahead of the report, to -0.1274 from -0.1475, and remains negative. Shares entered the release at $4.99, up 8.5% since the open following the August report. That gain partly reflects a rebound from a 52-week low of $4.45 set on October 1. The stock sits 20.6% below its $6.29 200-day moving average and 7.4% below its October high of $5.39. The Earnings Whispers momentum and AVWAP trend readings remain negative. The modest pre-report bounce now has to absorb another miss and another reset.

The bottom line is that this report pushed Nu Skin's recovery timeline further out rather than validating it. Revenue landing within guidance and the improved Prysm iO conversion offer real but narrow positives. Against them stand a 52.4% earnings miss, accelerating core declines, contracting core margins and a third consecutive guidance cut. Until device placements, sales leaders and customer counts stop shrinking, investors have little reason to treat management's projections as a floor.